The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Drug Manufacturers - Other > North American Vaccine, Inc.

North American Vaccine, Inc.
 PROFILE
North American Vaccine (NAV) produces that childhood rite of passage: the shot. NAV's flagship product is Certiva, a whooping cough vaccine that has been combined with diphtheria and tetanus toxoids to form a single vaccine. It has been approved in Germany, Sweden, Denmark (where an anti-polio component has been added), and the US. NAV is also developing several combination vaccines using Certiva as an anchor component, as well as a new group of vaccines for bacterial infections. Abbott Laboratories is terminating its agreement to distribute Certiva; NAV is seeking a new distribution partner. The company is a subsidiary of Baxter International.

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 11.00
1-Yr. Sales Growth: 31.0%
Employees: 267
Revenue per employee: $41,198.50

 KEY PEOPLE
• Randal D. Chase
    CEO
• Lawrence J. Hineline
    CFO

 CONTACT INFO
10150 Old Columbia Rd.
Columbia, MD 21046
US
Phone: 410-309-7100
Fax: 410-381-8456
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001